Intellectual Property Rights (IPRs) as Core Assets

[Patents per product: see table below – Patents per technology/use: see table and image below]

 

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community. Innovation represents one of the strongest pillars of the company with more than 30 in-house scientists and a unique network of talented and renowned medical doctors contributing to Regen Lab’s Research & Development.

Over more than 10 years, this innovation has been secured by building substantial patent & trademarks portfolios. Intellectual Property Rights (IPRs) therefore represent core assets of the company protecting its unique products and forging Regen Lab’s renowned brand names.

The patent portfolio can be divided into two core technologies:

  1. PRP (proprietary gel method) alone or in combination with cell extracts and associated key technologies like Autologous Thrombin Serum (ATS) and PRP Cell Culture which are covered by U.S. patent US8529957 and US9833478, European Patent EP2073862B, Australian Patent AU2013203115B and Patents Pending including US2016158286, WO2016/083549, Divisional of EP2073862 and Divisonals arising out of WO2011/110948.

Associated trademarks are REGENLAB, REGENKIT, REGENACR, PRP, A-PRP, REGENCELL, REGENPLASMA, REGEN PRP, REGEN EXTRACELL, THT, fig.cellularmask, CUTECELLS, REGENVET, A-CPKIT which are registered trademarks of Regen Lab SA in Europe, United States and other countries.

 

  1. Hyaluronic acid alone or in combination with PRP leading to the unique “all in one” Cellular Matrix product combining in a synergetic manner the advantageous properties of PRP and HA, which are covered by U.S. patents US8945537 and US9517255, European patent EP2544697B1, Canadian Patent CA2789533C, Chinese Patent CN103079577, Japanese patent JP6076091, Australian Patent AU2011225828B, Russian patent RU2614722 and Patents Pending including KR20130067247, 7167/DELNP/2012, HKA.13104932.8, US2015151858 and EP2771241.


Associated trademarks are REGENLAB, REGENKIT, CELLULAR MATRIX fig., SKINVISC, ARTHROVISC, REGENMATRIX, PRP and A-PRP which are registered trademarks of Regen Lab SA in Europe, United States and other countries.

Table: Patents per product

Product Sub-category Article names Ref. Patents
Medical devices for the preparation of a platelet concentrate (A-PRP) RegenACR-C RegenACR-C Cellular Mask Adv. R-ACR CMC/B WO2008/023026, WO2016/083549, U.S. patent US8529957 and US9833478, European Patent EP2073862B and Patents Pending including US2016158286, Continuation of US2009/0317439, Divisional of EP2073862, Divisonals arising out of WO2011/110948, CH696752
RegenACR-C Cellular Mask R-ACR CM/B
RegenACR-C Classic R-ACR C1/B
RegenACR-C Extra R-ACR C2/B
RegenACR-C Plus R-ACR C/BA
RegenKit Surgery RegenKit Ophthalmology R-OPH/B
RegenKit Surgery RK-SRG AZ/BA1
RegenKit BCT RegenKit-BCT-1 RK-BCT-1
RegenKit-BCT-2 RK-BCT-2
RegenKit-BCT-2 Plus RK-BCT-2A
RegenKit-BCT-3 RK-BCT-3
RegenKit-BCT-4 RK-BCT-4
RegenKit Extracell RegenKit Extracell Adipocyte RK-EXA-B2
RegenKit Extracell Adipocyte RK-EXA-B4
A-CP Kits A-CP-Kit-1 A-CP-1
A-CP-Kit-2 A-CP-2
A-CP-Kit-2 Plus A-CP-2A
A-CP-Kit-3 A-CP-3
A-CP-Kit-3 ATS A-CP-3A
A-CP-Kit-4 A-CP-4
Regen Fibrin Polymer Regen Fibrin Polymer 1 R-FP1/T
Regen Fibrin Polymer 2 R-FP2/T
RegenKit Extracell RegenKit Extracell Membrane R-EXM/T
RegenKit Extracell BMC R-EXB/T
RegenKit Extracell BMC R-EXB/T2
RegenKit Extracell Glue RK-EXG/T
RegenKit Surgery RegenKit Surgery RK-SRG AZ/TA1
RegenKit THT RegenKit-THT-1 RK-THT-1
RegenKit-THT-2 RK-THT-2
RegenKit-THT-2 Plus RK-THT-2A
RegenKit-THT-3 RK-THT-3
RegenKit-THT-4 RK-THT-4
Medical devices for the preparation of autologous thrombin serum (ATS) RegenKit ATS &
A-CP Kit
RegenKit-ATS-3 RK-ATS-3 WO2011/110948, Australian Patent AU2013203115B, CA2915649, Patent pending in China, Patent pending in Japan
A-CP-Kit-3 ATS A-CP-3A
Medical devices for the preparation of a platelet concentrate (A-PRP) in combination with Hyaluronic Acid (HA) Cellular Matrix Cellular Matrix BCT-HA Kit BCT-HA-3 WO2011/110948, WO2013/061309, WO2016/083549, U.S. patent US8945537, U.S. patent US9517255, European patent EP2544697B1, Canadian Patent CA2789533C, Chinese Patent CN103079577B, Japanese patent JP6076091, Australian Patent AU2011225828B, Israeli Patent IL221133, Russian patent RU2614722 and Patents Pending including KR20130067247, 7167/DELNP/2012, HKA.13104932.8, US2015151858 and EP2771241
Cellular Matrix A-CP-HA Kit ACP-HA-3
Medical devices containing HA Viscokits ArthroVisc Kit ARV-HA40-1 WO2013/061309, Patents Pending US2015151858 and EP2771241
SkinVisc Kit SKV-HA40-1

Image: Patents per technology/use

 

Version: 5 – Published online on 2019-10-10


Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /home/clients/debda59660661329b16e26debc991bbb/web/corporate/wp-includes/functions.php on line 3778

Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /home/clients/debda59660661329b16e26debc991bbb/web/corporate/wp-includes/functions.php on line 3778